Xeris Biopharma Holdings (XERS) Research & Development (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Research & Development came in at $8.8 million in Q1 2026, up 13.29% YoY from $7.8 million in Q1 2025, and up 11.54% on a QoQ basis from $7.9 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Research & Development (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Research & Development data on file, last reported at $8.8 million in Q1 2026.
- Quarterly Research & Development rose 13.29% year-over-year to $8.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.2 million (up 26.29% YoY) and the FY2025 annual result came in at $31.2 million, up 21.93% from the prior year.
- Research & Development rose to $8.8 million in Q1 2026, from $7.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $8.8 million in Q1 2026 to a low of $3.7 million in Q2 2022.
- A 5-year average of $6.4 million and a median of $6.1 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development tumbled 50.85% — and 2023, when it soared 63.72%.
- Tracing XERS's Research & Development over 5 years: stood at $5.0 million in 2022, then climbed by 28.8% to $6.4 million in 2023, then dropped by 4.54% to $6.1 million in 2024, then advanced by 29.25% to $7.9 million in 2025, then climbed by 11.54% to $8.8 million in 2026.
- The last three Research & Development figures came in at $8.8 million (Q1 2026), $7.9 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn | 10.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.67 Mn |
| Mar 31, 2026 | 8.78 Mn |
| Dec 31, 2025 | 7.87 Mn |
| Sep 30, 2025 | 7.48 Mn |
| Jun 30, 2025 | 8.06 Mn |
| Mar 31, 2025 | 7.75 Mn |
| Dec 31, 2024 | 6.09 Mn |
| Sep 30, 2024 | 5.89 Mn |
| Jun 30, 2024 | 5.76 Mn |
| Mar 31, 2024 | 7.82 Mn |
| Dec 31, 2023 | 6.38 Mn |
| Sep 30, 2023 | 5.03 Mn |
| Jun 30, 2023 | 6.09 Mn |
| Mar 31, 2023 | 4.84 Mn |
| Dec 31, 2022 | 4.96 Mn |
| Sep 30, 2022 | 6.04 Mn |
| Jun 30, 2022 | 3.72 Mn |
| Mar 31, 2022 | 6.25 Mn |
| Dec 31, 2021 | 10.08 Mn |
| Sep 30, 2021 | 5.66 Mn |